Guidewire Outlines Vision That Offers Competitive Advantages for Global Insurers at the Guidewire Insurance Forum in Paris
25.3.2025 11:00:00 CET | Business Wire | Press release
Guidewire (NYSE: GWRE) held its annual European Insurance Forum event on 25 March at La Maison de la Mutualité in Paris. The largest-ever Guidewire event in Europe drew more than 375 attendees from 16 countries, a sign of Guidewire's market-leading presence in Europe which has expanded to include 76 customers across 19 countries with 30 selecting Guidewire Cloud Platform, 90 technology partners, 4,000 consultants and 950 employees.
At the Insurance Forum, Guidewire detailed its vision to increase agility and eliminate operational friction across the P&C insurance industry through the comprehensive and integrated Guidewire Cloud Platform—with innovations from product design to pricing and rating, digital engagement, data and analytics, AI and a robust app marketplace—to help insurers remain competitive in a rapidly evolving market.
Four of Guidewire’s Europe-based customers shared stories of transformation from the main stage, along with unique insights on hot topics, including leveraging automation to modernize claims management, delivering enhanced customer experiences, redefining microinsurance operations and advancing commercial lines success with analytics.
In keynote remarks delivered by Guidewire CEO Mike Rosenbaum, Chief Product Development Officer Diego Devalle and Managing Director, EMEA, Will McAllister, Guidewire noted they expect the industry to derive tremendous value from applications of Generative AI (GenAI) across the P&C lifecycle. To that end, Guidewire is extending their platform to include an Agentic AI Development Framework, focused initially on improving developer efficiency and enabling intelligent experiences for underwriters and claims adjusters.
Three ongoing strategic initiatives were also highlighted, including:
Redefining underwriting excellence - Guidewire described the first in a series of capabilities designed to reshape the underwriting process in P&C - transforming risk assessment from a reactive process to a dynamic, intelligence-driven decision engine. They discussed a solution that will apply Agentic AI to automatically extract, enrich, and summarize data from new business submissions to reduce manual data entry while allowing underwriters to make faster and better-informed decisions.
Elevating the claims experience - Guidewire demonstrated how Agentic AI can improve the claims adjuster experience and streamline claims handling. This included an AI-based Adjuster Assistant automatically generating high-level summaries of claim files and attached documents that surface the most relevant, actionable information and provide guidance on next steps.
Integrated pricing and rating vision - Guidewire shared how insurers of the future could unlock the power of an advanced actuarial pricing engine on Guidewire Cloud Platform, making static, one-size-fits-all pricing a thing of the past. To accelerate progress against this vision, Guidewire has signed a definitive agreement to acquire Quantee, a Poland-based insurtech startup specializing in dynamic pricing software.
“The Guidewire Insurance Forum in Paris is the largest event we have ever held in Europe, and it’s where P&C insurance leaders and technology experts meet to advance the future of the industry in Europe,” said Will McAllister, SVP and managing director, EMEA, at Guidewire. “Guidewire’s clear vision for product and service excellence in EMEA, including an integrated core platform that delivers the insights and engagement tools insurers need to grow efficiently in unprecedented market and environmental conditions, is helping European insurers to shape a more agile, responsive and impactful insurance industry of the future.”
About Guidewire
Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. More than 570 insurers in 42 countries, from new ventures to the largest and most complex in the world, rely on Guidewire products. With core systems leveraging data and analytics, digital, and artificial intelligence, Guidewire defines cloud platform excellence for P&C insurers.
We are proud of our unparalleled implementation record, with 1,700+ successful projects supported by the industry’s largest R&D team and SI partner ecosystem. Our marketplace represents the largest solution partner community in P&C, where customers can access hundreds of applications to accelerate integration, localization, and innovation.
For more information, please visit www.guidewire.com and follow us on X (formerly known as Twitter) and LinkedIn.
NOTE: For information about Guidewire trademarks, visit https://www.guidewire.com/legal-notices.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325477010/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom